Droplet PCR System Identifies Fetal Genetic Data
By HospiMedica International staff writers Posted on 24 Nov 2015 |
A new study describes a simple, accurate, and low risk blood test that can detect fetal blood group, sex, and genetic conditions from a maternal blood sample.
Developed by researchers at Plymouth University (United Kingdom), the new noninvasive fetal Rh blood group and D antigen (RhD) genotyping test can help prevent unnecessary administration of prophylactic anti-D to women carrying RHD-negative fetuses. The blood sample can be taken from the mother when she has her first appointment with a general practitioner (GP) or midwife at the early stages of pregnancy, negating the need for multiple appointments and making best use of healthcare resources.
A study to validate the new test, which is based on a novel droplet digital polymerase chain reaction (ddPCR) platform to detect the cell-free fetal DNA (cffDNA) fraction, found that dPCR demonstrated 100% sensitivity for both fetal sex determination and RHD genotyping. The test can also be carried out on mothers at risk of X-linked genetic recessive diseases, including hemophilia and Duchenne muscular dystrophy, as well as mothers at risk of hemolytic disease of the newborn. The study was published in the November 2015 issue of Clinical Chemistry.
“Use of dPCR for identification of fetal specific markers can reduce the occurrence of false-negative and inconclusive results, particularly when samples express high levels of background maternal cell-free DNA,” concluded senior author Prof. Neil Avent, PhD, of the Plymouth University School of Biomedical and Healthcare Sciences. “The technique represents a comparatively low-risk method for the early identification of a number of conditions, which in turn will aid earlier diagnosis and possible therapies to the potential benefit of both mother and child.”
ddPCR is based on water-oil emulsion droplet technology; a sample is fractionated into 20,000 nanoliter-sized droplets, serving essentially the same function as individual test tubes or wells in a PCR plate, albeit in a much smaller format. The massive sample partitioning is a key aspect of the ddPCR technology, enabling high-throughput digital PCR in a manner that uses lower sample and reagent volumes and reduces overall cost, while still maintaining the sensitivity and precision of current digital PCR systems.
Related Links:
Plymouth University
Developed by researchers at Plymouth University (United Kingdom), the new noninvasive fetal Rh blood group and D antigen (RhD) genotyping test can help prevent unnecessary administration of prophylactic anti-D to women carrying RHD-negative fetuses. The blood sample can be taken from the mother when she has her first appointment with a general practitioner (GP) or midwife at the early stages of pregnancy, negating the need for multiple appointments and making best use of healthcare resources.
A study to validate the new test, which is based on a novel droplet digital polymerase chain reaction (ddPCR) platform to detect the cell-free fetal DNA (cffDNA) fraction, found that dPCR demonstrated 100% sensitivity for both fetal sex determination and RHD genotyping. The test can also be carried out on mothers at risk of X-linked genetic recessive diseases, including hemophilia and Duchenne muscular dystrophy, as well as mothers at risk of hemolytic disease of the newborn. The study was published in the November 2015 issue of Clinical Chemistry.
“Use of dPCR for identification of fetal specific markers can reduce the occurrence of false-negative and inconclusive results, particularly when samples express high levels of background maternal cell-free DNA,” concluded senior author Prof. Neil Avent, PhD, of the Plymouth University School of Biomedical and Healthcare Sciences. “The technique represents a comparatively low-risk method for the early identification of a number of conditions, which in turn will aid earlier diagnosis and possible therapies to the potential benefit of both mother and child.”
ddPCR is based on water-oil emulsion droplet technology; a sample is fractionated into 20,000 nanoliter-sized droplets, serving essentially the same function as individual test tubes or wells in a PCR plate, albeit in a much smaller format. The massive sample partitioning is a key aspect of the ddPCR technology, enabling high-throughput digital PCR in a manner that uses lower sample and reagent volumes and reduces overall cost, while still maintaining the sensitivity and precision of current digital PCR systems.
Related Links:
Plymouth University
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration